These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10211785)

  • 1. Binding of EGF peptide and EGF receptor antibodies and its fragments in different tumor models.
    Senekowitsch-Schmidtke R
    Hybridoma; 1999 Feb; 18(1):29-35. PubMed ID: 10211785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425.
    Senekowitsch-Schmidtke R; Steiner K; Haunschild J; Möllenstädt S; Truckenbrodt R
    Cancer Immunol Immunother; 1996 Feb; 42(2):108-14. PubMed ID: 8620519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.
    Mendelsohn J
    J Natl Cancer Inst Monogr; 1992; (13):125-31. PubMed ID: 1389685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
    Masui H; Kawamoto T; Sato JD; Wolf B; Sato G; Mendelsohn J
    Cancer Res; 1984 Mar; 44(3):1002-7. PubMed ID: 6318979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-epidermal growth factor receptor monoclonal antibodies affecting signal transduction.
    Reins HA; Steinhilber G; Freiberg B; Anderer FA
    J Cell Biochem; 1993 Feb; 51(2):236-48. PubMed ID: 8382707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer.
    Teramoto T; Onda M; Tokunaga A; Asano G
    Cancer; 1996 Apr; 77(8 Suppl):1639-45. PubMed ID: 8608556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
    Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ
    Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications.
    Mendelsohn J
    Trans Am Clin Climatol Assoc; 1989; 100():31-8. PubMed ID: 3077575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
    Deguchi Y; Kurihara A; Pardridge WM
    Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
    Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
    J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
    Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas.
    Tysnes BB; Haugland HK; Bjerkvig R
    Invasion Metastasis; 1997; 17(5):270-80. PubMed ID: 9876221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
    Ye D; Mendelsohn J; Fan Z
    Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionic signal transduction in growth factor action.
    De Laat SW; Moolenaar WH; Defize LH; Boonstra J; van der Saag PT
    Biochem Soc Symp; 1985; 50():205-20. PubMed ID: 3019351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR).
    Zhu L; Zhao L; Wu M; Chen Z; Li H
    Immunol Lett; 2013 Jun; 153(1-2):33-40. PubMed ID: 23871733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies.
    Mendelsohn J
    Semin Cancer Biol; 1990 Oct; 1(5):339-44. PubMed ID: 2103507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.